Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park(The University of Texas MD Anderson Cancer Center), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Kenneth J. O’Byrne(Translational Research Institute), Vera Hirsh(Taipei Veterans General Hospital), Dan Massey(Taipei Veterans General Hospital), Catherine Dubos Arvis(Centre François Baclesse), James Chih‐Hsin Yang(National Taiwan University Hospital), Tony Mok(Chinese University of Hong Kong), Victoria Zazulina(Taipei Veterans General Hospital), Michael Boyer(Chris O’Brien Lifehouse), Scott A. Laurie(Ottawa Hospital), Janessa Laskin(BC Cancer Agency), Li Zhang(Jinan Stomatological Hospital), Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Miyoung Kim(Boehringer Ingelheim (Germany)), Mehdi Shahidi(Taipei Veterans General Hospital), Karl Kölbeck(Karolinska University Hospital), Dong‐Wan Kim(Seoul National University Hospital), Sang-We Kim(Asan Medical Center), Chun-Ming Tsai(Taipei Veterans General Hospital), Shun Lü(Shanghai Jiao Tong University), Eng-Huat Tan(National Cancer Centre Singapore), Ki Hyeong Lee(Chungbuk National University Hospital)
Cited by 1,173
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k